Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection

  1. Alexander M Price
  2. Joanne Dai
  3. Quentin Bazot
  4. Luv Patel
  5. Pavel A Nikitin
  6. Reza Djavadian
  7. Peter S Winter
  8. Cristina A Salinas
  9. Ashley Perkins Barry
  10. Kris C Wood
  11. Eric C Johannsen
  12. Anthony Letai
  13. Martin J Allday
  14. Micah A Luftig  Is a corresponding author
  1. Duke University School of Medicine, United States
  2. Imperial College London, United Kingdom
  3. Harvard Medical School, United States
  4. University of Wisconsin School of Medicine and Public Health, United States
  5. Duke University, United States

Abstract

Latent Epstein-Barr virus (EBV) infection is causally linked to several human cancers. EBV expresses viral oncogenes that promote cell growth and inhibit the apoptotic response to uncontrolled proliferation. The EBV oncoprotein LMP1 constitutively activates NFB and is critical for survival of EBV-immortalized B cells. However, during early infection EBV induces rapid B cell proliferation with low levels of LMP1 and little apoptosis. Therefore, we sought to define the mechanism of survival in the absence of LMP1/NFB early after infection. We used BH3 profiling to query mitochondrial regulation of apoptosis and defined a transition from uninfected B cells (BCL-2) to early-infected (MCL-1/BCL-2) and immortalized cells (BFL-1). This dynamic change in B cell survival mechanisms is unique to virus-infected cells and relies on regulation of MCL-1 mitochondrial localization and BFL-1 transcription by the viral EBNA3A protein. This study defines a new role for EBNA3A in the suppression of apoptosis with implications for EBV lymphomagenesis.

Data availability

The following previously published data sets were used
    1. Zhao B
    2. Zou JY
    3. Wang H
    4. Johannsen E
    5. Aster J
    6. Bernstein B
    7. Kieff E
    (2011) EBNA2 ChIP-Seq
    Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE29498).
    1. Shoresh N
    (2011) Histone modifications in LCLs (ENCODE)
    Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE29611).
    1. Snyder M
    2. Gerstein M
    3. Weissman S
    4. Farnham P
    5. Struhl K
    (2011) TF binding sites in LCLs (ENCODE)
    Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE31477).

Article and author information

Author details

  1. Alexander M Price

    Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, United States
    Competing interests
    No competing interests declared.
  2. Joanne Dai

    Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, United States
    Competing interests
    No competing interests declared.
  3. Quentin Bazot

    Molecular Virology, Division of Infectious Diseases, Department of Medicine, Imperial College London, London, United Kingdom
    Competing interests
    No competing interests declared.
  4. Luv Patel

    Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  5. Pavel A Nikitin

    Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, United States
    Competing interests
    No competing interests declared.
  6. Reza Djavadian

    McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, United States
    Competing interests
    No competing interests declared.
  7. Peter S Winter

    Department of Pharmacology and Cancer Biology, Duke University, Durham, United States
    Competing interests
    No competing interests declared.
  8. Cristina A Salinas

    Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, United States
    Competing interests
    No competing interests declared.
  9. Ashley Perkins Barry

    Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, United States
    Competing interests
    No competing interests declared.
  10. Kris C Wood

    Department of Pharmacology and Cancer Biology, Duke University, Durham, United States
    Competing interests
    No competing interests declared.
  11. Eric C Johannsen

    McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, United States
    Competing interests
    No competing interests declared.
  12. Anthony Letai

    Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States
    Competing interests
    Anthony Letai, Is a paid advisor to, and his laboratory receives research sponsorship from, AbbVie, Astra-Zeneca, and Tetralogic..
  13. Martin J Allday

    Molecular Virology, Division of Infectious Diseases, Department of Medicine, Imperial College London, London, United Kingdom
    Competing interests
    No competing interests declared.
  14. Micah A Luftig

    Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, United States
    For correspondence
    micah.luftig@duke.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2964-1907

Funding

National Cancer Institute (R01-CA140337)

  • Micah A Luftig

American Cancer Society (RSG-13-228-01-MPC)

  • Micah A Luftig

Wellcome (099273/Z/12/Z)

  • Quentin Bazot
  • Martin J Allday

National Institute for Dental and Cranofacial Research (R01-DE025994)

  • Joanne Dai
  • Micah A Luftig

National Institute for Allergy and Infectious Diseases (5P30-AI064518)

  • Micah A Luftig

National Cancer Institute (F31-CA180451)

  • Alexander M Price

National Institute for Dental and Cranofacial Research (R01-DE023939)

  • Eric C Johannsen

National Institute for Allergy and Infectious Diseases (T32-AI078985)

  • Reza Djavadian

National Cancer Institute (R01-CA129974)

  • Anthony Letai

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Stephen P Goff, Howard Hughes Medical Institute, Columbia University, United States

Publication history

  1. Received: October 19, 2016
  2. Accepted: April 19, 2017
  3. Accepted Manuscript published: April 20, 2017 (version 1)
  4. Version of Record published: May 10, 2017 (version 2)

Copyright

© 2017, Price et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,924
    Page views
  • 639
    Downloads
  • 26
    Citations

Article citation count generated by polling the highest count across the following sources: Scopus, Crossref, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Alexander M Price
  2. Joanne Dai
  3. Quentin Bazot
  4. Luv Patel
  5. Pavel A Nikitin
  6. Reza Djavadian
  7. Peter S Winter
  8. Cristina A Salinas
  9. Ashley Perkins Barry
  10. Kris C Wood
  11. Eric C Johannsen
  12. Anthony Letai
  13. Martin J Allday
  14. Micah A Luftig
(2017)
Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection
eLife 6:e22509.
https://doi.org/10.7554/eLife.22509

Further reading

    1. Biochemistry and Chemical Biology
    2. Cancer Biology
    David J Hosfield et al.
    Research Article

    Chemical manipulation of estrogen receptor alpha ligand binding domain structural mobility tunes receptor lifetime and influences breast cancer therapeutic activities. Selective estrogen receptor modulators (SERMs) extend ERα cellular lifetime/accumulation. They are antagonists in the breast but agonists in the uterine epithelium and/or in bone. Selective estrogen receptor degraders/downregulators (SERDs) reduce ERα cellular lifetime/accumulation and are pure antagonists. Activating somatic ESR1 mutations Y537S and D538G enable resistance to first-line endocrine therapies. SERDs have shown significant activities in ESR1 mutant setting while few SERMs have been studied. To understand whether chemical manipulation of ERα cellular lifetime and accumulation influences antagonistic activity, we studied a series of methylpyrollidine lasofoxifene derivatives that maintained the drug's antagonistic activities while uniquely tuning ERα cellular accumulation. These molecules were examined alongside a panel of antiestrogens in live cell assays of ERα cellular accumulation, lifetime, SUMOylation, and transcriptional antagonism. High-resolution x-ray crystal structures of WT and Y537S ERα ligand binding domain in complex with the methylated lasofoxifene derivatives or representative SERMs and SERDs show that molecules that favor a highly buried helix 12 antagonist conformation achieve the greatest transcriptional suppression activities in breast cancer cells harboring WT/Y537S ESR1. Together these results show that chemical reduction of ERα cellular lifetime is not necessarily the most crucial parameter for transcriptional antagonism in ESR1 mutated breast cancer cells. Importantly, our studies show how small chemical differences within a scaffold series can provide compounds with similar antagonistic activities, but with greatly different effects of the cellular lifetime of the ERα, which is crucial for achieving desired SERM or SERD profiles.

    1. Biochemistry and Chemical Biology
    2. Cancer Biology
    Yanchun Zhang et al.
    Research Article

    Tyrosine phosphorylation, orchestrated by tyrosine kinases and phosphatases, modulates a multi-layered signaling network in a time- and space-dependent manner. Dysregulation of this post-translational modification is inevitably associated with pathological diseases. Our previous work has demonstrated that non-receptor tyrosine kinase FER is upregulated in ovarian cancer, knocking down which attenuates metastatic phenotypes. However, due to the limited number of known substrates in the ovarian cancer context, the molecular basis for its pro-proliferation activity remains enigmatic. Here, we employed mass spectrometry and biochemical approaches to identify insulin receptor substrate 4 (IRS4) as a novel substrate of FER. FER engaged its kinase domain to associate with the PH and PTB domains of IRS4. Using a proximity-based tagging system in ovarian carcinoma-derived OVCAR-5 cells, we determined that FER-mediated phosphorylation of Tyr779 enables IRS4 to recruit PIK3R2/p85β, the regulatory subunit of PI3K, and activate the PI3K-AKT pathway. Rescuing IRS4-null ovarian tumor cells with phosphorylation-defective mutant, but not WT IRS4 delayed ovarian tumor cell proliferation both in vitro and in vivo. Overall, we revealed a kinase-substrate mode between FER and IRS4, and the pharmacological inhibition of FER kinase may be beneficial for ovarian cancer patients with PI3K-AKT hyperactivation.